Relmada Therapeutics Inc. (NASDAQ: RLMD) is a clinical-stage biopharmaceutical company that specializes in developing novel therapies for the treatment of central nervous system (CNS) diseases, particularly those related to pain management. With its significant portfolio, the company is poised to address several substantial unmet medical needs in the global therapeutic market.
Founded in 2004 and headquartered in New York, Relmada Therapeutics is dedicated to delivering life-changing solutions to patients suffering from CNS disorders. The company combines cutting-edge science and clinically validated methodologies to advance the development of its pioneering CNS therapeutical offerings.
The flagship candidate of Relmada's product portfolio is REL-1017, a N-methyl-D-aspartate (NMDA) receptor antagonist, currently in Phase 3 clinical trials as a treatment for major depressive disorder (MDD). REL-1017 works by modulating the glutamatergic system, which holds significant potential for treating various mood and cognitive disorders. This investigational drug has been given Fast Track designation by the U.S. Food and Drug Administration (FDA), indicating the urgency of developing a drug for this severe and life-threatening condition. If approved, it could provide substantial improvements over existing therapies.
Relmada Therapeutics has a unique platform for progressing medicines from novel drug discovery through to late-stage clinical development. Fueled by a devoted team of distinguished specialists and a proficient and seasoned management squad that collectively has extensive experience in drug development and commercialization, the company is well-equipped to take on the various challenges of CNS drug production.
The company's strategic endeavors are also financed robustly, an aspect that enhances its flexibility and capability to deliver its business objectives on time. As part of its financial strategy, Relmada accomplished a $115 million public offering in June 2020, which has strengthened the company’s balance sheet and will facilitate the continued development of its pipeline candidates.
Relmada Therapeutics is paving the way in CNS disorders. With the substantial progress the company is making in the clinical development of REL-1017, it is on track to potentially deliver a significant new treatment option for MDD. Above all, Relmada Therapeutics remains committed to sourcing, developing, and commercializing novel therapeutics that could improve the lives of patients battling CNS conditions around the world.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Relmada Therapeutics (RLMD) has seen its fair value decreased by 15% to $10.75, despite recent inclusions in several Russell indexes which could expand its market presence. Analysts adjusted the price target due to updated assumptions for growth and profitability, though they highlighted continued interest in the company's NDV-01 intravesical chemotherapy platform. The valuation changes reflect a lower projected revenue growth rate and a slightly more conservative view on future profitability.
Relmada Therapeutics (RLMD) shares rose by almost 11% in afternoon trading on Friday after the company's CEO and CFO each purchased 200,000 shares. The article states that a premium subscription is required to read the full details of this MT Newswires article.
Relmada Therapeutics CEO Sergio Traversa recently purchased 200,000 shares of the company's common stock for $828,000 through open market transactions. These purchases increased his direct holdings to 1,500,000 shares, coming as the stock has seen significant gains despite recent volatility. The insider buying occurs amidst analyst reports suggesting the stock is undervalued and recent news of narrower-than-expected losses but also manufacturing delays for its lead drug candidate.
_07_03_2026_03_50_21_133108.jpg)
Relmada Therapeutics CEO and Director, Sergio Traversa, purchased a total of 200,000 shares of the company's common stock in open market transactions on September 9 and 10, 2026. These purchases, detailed in a Form 4 SEC filing, increased his direct beneficial ownership to 1,500,000 shares. The transactions involved weighted average prices of $4.18 per share on the first day and $4.10 per share on the second.
Relmada Therapeutics, a clinical-stage biotechnology company, announced its senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference in Boston from September 8-10, 2026. The company focuses on developing therapies for oncology and central nervous system disorders, with lead candidates NDV-01 and sepranolone. Interested parties are encouraged to contact their Wells Fargo representative to arrange a meeting.
Relmada Therapeutics, a clinical-stage biotechnology company, announced its participation in the Wells Fargo 21st Annual Healthcare Conference. Senior management will engage in one-on-one meetings with interested parties from September 8 - 10, 2026. The company focuses on developing therapies for oncology and central nervous system disorders.
Relmada Therapeutics, a clinical-stage biotechnology company, announced its senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference in Boston from September 8-10, 2026. The company focuses on developing therapies for oncology and central nervous system disorders. Interested parties are encouraged to contact their Wells Fargo representative to arrange a meeting.